RecruitingNCT06933108

Prediction of Peripheral Neuropathy With Functional Testing

Estimate the Risk of Diabetic and Uremic Peripheral Neuropathy Using Physical and Functional Testing


Sponsor

Université catholique de l'Ouest

Enrollment

70 participants

Start Date

Jan 27, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Diabetes and chronic kidney disease (CKD) are two distinct pathologies. The former is defined as an impairment in insulin production and/or utilization, while the latter refers to structural or functional abnormalities of the kidneys. However, these two diseases share a common complication: peripheral neuropathy. This condition affects between 50% and 60% of patients with diabetes or CKD. Peripheral neuropathy involves the destruction of sensory and motor neurons, leading to a wide range of painful symptoms while also reducing force production capacity. Among the diagnostic tests used, the most accessible clinical tests suffer from high variability due to human subjectivity (e.g., the tuning fork test, which requires examiner expertise and verbal patient feedback), whereas laboratory electrophysiological tests can only detect the largest neurons, which are affected at later stages. Although composite clinical tests have been developed to improve neuropathy screening performance, they still inherit the limitations of their individual components. In other words, they remain subject to variability related to the examiner's experience and the patient's ability to understand instructions, while also being performed through various procedures that lack a standardized consensus. Moreover, these composite scores are particularly time-consuming and are therefore rarely used in clinical practice. As a result, no method currently allows for large-scale, early, and reliable screening of peripheral neuropathy. Our recent work and emerging studies suggest that assessing functional capacities could serve as an objective and early marker of neuropathic impairment, even before clinical diagnosis. Specifically, the quantification of postural balance performance using stabilometric methods (i.e., center of pressure displacement area) and unipedal balance time could predict the presence of diabetes-related peripheral neuropathy with over 95% accuracy compared to diagnosis with a composite clinical method (unpublished results). Therefore, the aim of this study is to evaluate physical and balance capacities assessed during routine care in adapted physical activity settings, in order to determine whether the development of a composite score could help estimate the risk of peripheral neuropathy in individuals with diabetes and CKD.


Eligibility

Min Age: 60 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study aims to predict which patients receiving chemotherapy will develop nerve damage in their hands and feet — a side effect called peripheral neuropathy — by using functional tests before treatment begins. Early prediction could help doctors take steps to prevent or reduce this painful condition. **You may be eligible if...** - You are scheduled to receive chemotherapy known to cause nerve damage (such as taxanes or platinum-based drugs) - You are an adult with cancer who has not yet started this course of chemotherapy - You are willing to undergo simple nerve and balance tests **You may NOT be eligible if...** - You already have significant nerve damage (neuropathy) from diabetes, prior chemotherapy, or other causes - You have conditions that affect nerve function independent of chemotherapy - You are unable to perform the required functional tests Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Centre Hospitalier Le Mans

Le Mans, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06933108


Related Trials